Epidarex Capital

Harness Therapeutics is a private biotechnology company focused on developing SINEUPs, a novel class of therapeutic RNAs that upregulate protein expression with precise control and specificity. The company’s platform uses mRNA-targeted oligonucleotides to modulate post-transcriptional protein synthesis, enabling disease-modifying protein upregulation for conditions that have resisted traditional approaches. Its work centers on central nervous system and ophthalmologic disorders, with potential applications across multiple therapy areas by expanding the druggable proteome beyond what conventional small molecules, biologics, or gene therapies can address.

Epsilogen Ltd is an immuno-oncology company based in London, United Kingdom, founded in 2016. The company specializes in developing immunoglobulin E (IgE) antibodies aimed at treating cancer. Epsilogen offers a portfolio of IgE candidates that specifically target cancer antigens such as HER2, EGFR, and PD-L1. Its innovative IgE platform supports the development and validation of novel antibodies, allowing for enhanced potency, improved tumor access, and a prolonged presence in tissue. This focus on IgE-based therapies positions Epsilogen to provide effective treatment options for patients with solid tumors.

Theolytics Limited is a clinical-stage biotechnology company based in Oxford, United Kingdom, specializing in the development of oncolytic viral therapies to combat cancer. Founded in 2017, Theolytics utilizes a phenotypic screening platform that facilitates the discovery and development of effective, targeted therapeutic candidates designed for intravenous delivery. The company's innovative approach is aimed at creating category-changing cancer treatments that can address both solid and liquid tumors. In addition to advancing its internal pipeline of programs, Theolytics is also forming strategic partnerships to enhance and expedite the development of its therapeutic offerings, ultimately striving to provide innovative care options for patients.

Curve Therapeutics Limited, established in 2019 and based in London, specializes in drug discovery with a focus on cancer. The company has developed an innovative screening platform that enables functional screening of diverse libraries against disease-associated targets within their native cellular environment. This platform is used to build a pipeline of novel cancer drugs targeting currently undruggable targets.

Enterprise Therapeutics is a United Kingdom-based drug discovery company founded in 2014 and based in Brighton. It develops novel disease-modifying therapies for respiratory diseases, including cystic fibrosis, asthma, and COPD, with a focus on addressing the underlying mechanisms of mucus congestion to improve breathing, reduce lung infections, and enhance patient quality of life.

Theolytics Limited is a clinical-stage biotechnology company based in Oxford, United Kingdom, specializing in the development of oncolytic viral therapies to combat cancer. Founded in 2017, Theolytics utilizes a phenotypic screening platform that facilitates the discovery and development of effective, targeted therapeutic candidates designed for intravenous delivery. The company's innovative approach is aimed at creating category-changing cancer treatments that can address both solid and liquid tumors. In addition to advancing its internal pipeline of programs, Theolytics is also forming strategic partnerships to enhance and expedite the development of its therapeutic offerings, ultimately striving to provide innovative care options for patients.

Nyra Medical is focused on creating innovative transcatheter heart valve repair technology specifically designed to treat mitral regurgitation. The company develops a structural heart device that modifies the native mitral valve using a proprietary implant, which helps to maintain the physiological geometry of the valve. This approach allows for a reproducible correction of valve regurgitation, offering a potential advancement in the treatment options available for patients suffering from this condition.

RapidPulse, Inc. is a privately held medical device company focused on creating minimally invasive vascular products specifically for the treatment of ischemic stroke. The company's flagship innovation is the RapidPulse™ Cyclic Aspiration System, which features an advanced aspiration pump designed to facilitate the rapid and consistent removal of blood clots from the brain. This technology aims to enhance patient outcomes in the neurovascular field. RapidPulse is a spinout from Syntheon LLC, a medical device incubator committed to developing groundbreaking products within the industry.

Harness Therapeutics is a private biotechnology company focused on developing SINEUPs, a novel class of therapeutic RNAs that upregulate protein expression with precise control and specificity. The company’s platform uses mRNA-targeted oligonucleotides to modulate post-transcriptional protein synthesis, enabling disease-modifying protein upregulation for conditions that have resisted traditional approaches. Its work centers on central nervous system and ophthalmologic disorders, with potential applications across multiple therapy areas by expanding the druggable proteome beyond what conventional small molecules, biologics, or gene therapies can address.

Kynos Therapeutics develops novel therapies targeting Kaiser-Meyer-Olkin (KMO), a key enzyme involved in inflammation, immunity, and metabolism. Its focus is on indications with unmet medical needs.

Epsilogen Ltd is an immuno-oncology company based in London, United Kingdom, founded in 2016. The company specializes in developing immunoglobulin E (IgE) antibodies aimed at treating cancer. Epsilogen offers a portfolio of IgE candidates that specifically target cancer antigens such as HER2, EGFR, and PD-L1. Its innovative IgE platform supports the development and validation of novel antibodies, allowing for enhanced potency, improved tumor access, and a prolonged presence in tissue. This focus on IgE-based therapies positions Epsilogen to provide effective treatment options for patients with solid tumors.

Dunad Therapeutics is a biopharmaceutical company focused on developing next-generation targeted protein degradation therapies. It provides a proprietary, tunable covalent chemistry platform that enables discovery and development of medicines that selectively and durably target disease drivers. The platform integrates disease biology with advanced chemistry to modulate protein stability and conformation, allowing the targeting of often undruggable proteins and enabling high-precision, durable therapeutic effects.

Leucid Bio is a biotechnology company focused on developing cell therapies for refractory solid tumors. It translates over two decades of King's College London research in CAR-T therapies, led by an experienced management team with scientific and commercial expertise.

Topas Therapeutics GmbH, established in 2013 and based in Hamburg, Germany, is a biotechnology company specializing in the development of nanoparticle-based therapeutics. The company's core focus is to induce antigen-specific immune tolerance, utilizing the liver's natural immunology capabilities to treat autoimmune diseases, allergies, and anti-drug antibodies. Topas' proprietary platform, Topas Particle Conjugates, targets liver sinusoidal endothelial cells, enabling tolerance against blood-borne antigens. The company has several clinical-stage programs, including TPM203 for pemphigus vulgaris, and collaborations with pharmaceutical giants like Eli Lilly and Boehringer Ingelheim. Topas Therapeutics is backed by prominent investors such as Epidarex Capital, Gimv, EMBL Ventures, Evotec, and Boehringer Ingelheim Venture Fund.

Macomics Ltd is an immuno-oncology company based in Edinburgh, United Kingdom, incorporated in 2018. The company specializes in the development of novel immunotherapies that modulate macrophages, a type of immune cell, to enhance the body’s defense against tumors. By targeting the immunosuppressive tumor microenvironment, Macomics aims to leverage disease-specific macrophage biology, thereby enabling healthcare providers and pharmaceutical companies to offer significant clinical benefits to patients suffering from cancer. Through its innovative approach, Macomics is dedicated to advancing precision medicines in the fight against cancer.

RapidPulse, Inc. is a privately held medical device company focused on creating minimally invasive vascular products specifically for the treatment of ischemic stroke. The company's flagship innovation is the RapidPulse™ Cyclic Aspiration System, which features an advanced aspiration pump designed to facilitate the rapid and consistent removal of blood clots from the brain. This technology aims to enhance patient outcomes in the neurovascular field. RapidPulse is a spinout from Syntheon LLC, a medical device incubator committed to developing groundbreaking products within the industry.

LUNAC Therapeutics is a biotechnology company focused on the development of advanced oral anticoagulant drugs aimed at treating and preventing life-threatening thrombotic events. The company's innovative drug formulations are designed to minimize bleeding risks in patients, allowing healthcare providers to manage high-risk patients with safe dose escalation. By addressing critical needs in anticoagulation therapy, LUNAC Therapeutics seeks to improve patient outcomes and enhance treatment options in the healthcare landscape.

Dunad Therapeutics is a biopharmaceutical company focused on developing next-generation targeted protein degradation therapies. It provides a proprietary, tunable covalent chemistry platform that enables discovery and development of medicines that selectively and durably target disease drivers. The platform integrates disease biology with advanced chemistry to modulate protein stability and conformation, allowing the targeting of often undruggable proteins and enabling high-precision, durable therapeutic effects.

Slate Bio is an immunotherapeutics development company focused on restoring the body's natural immunological response in autoimmune and inflammatory diseases. It develops therapies based on bifunctional cytokines to create a second, independent synergistic pathway characterized by tissue selectivity and enhanced pharmacodynamics, allowing for lower-dose treatments.

Theolytics Limited is a clinical-stage biotechnology company based in Oxford, United Kingdom, specializing in the development of oncolytic viral therapies to combat cancer. Founded in 2017, Theolytics utilizes a phenotypic screening platform that facilitates the discovery and development of effective, targeted therapeutic candidates designed for intravenous delivery. The company's innovative approach is aimed at creating category-changing cancer treatments that can address both solid and liquid tumors. In addition to advancing its internal pipeline of programs, Theolytics is also forming strategic partnerships to enhance and expedite the development of its therapeutic offerings, ultimately striving to provide innovative care options for patients.

Topas Therapeutics GmbH, established in 2013 and based in Hamburg, Germany, is a biotechnology company specializing in the development of nanoparticle-based therapeutics. The company's core focus is to induce antigen-specific immune tolerance, utilizing the liver's natural immunology capabilities to treat autoimmune diseases, allergies, and anti-drug antibodies. Topas' proprietary platform, Topas Particle Conjugates, targets liver sinusoidal endothelial cells, enabling tolerance against blood-borne antigens. The company has several clinical-stage programs, including TPM203 for pemphigus vulgaris, and collaborations with pharmaceutical giants like Eli Lilly and Boehringer Ingelheim. Topas Therapeutics is backed by prominent investors such as Epidarex Capital, Gimv, EMBL Ventures, Evotec, and Boehringer Ingelheim Venture Fund.

Libra Therapeutics is a biotechnology company dedicated to developing novel disease-modifying therapeutics for neurodegenerative diseases. Its platform focuses on restoring cellular balance through small molecule drugs that attenuate the production of neurotoxic proteins, targeting conditions such as amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer's, Parkinson's, and Huntington's disease.

Macomics Ltd is an immuno-oncology company based in Edinburgh, United Kingdom, incorporated in 2018. The company specializes in the development of novel immunotherapies that modulate macrophages, a type of immune cell, to enhance the body’s defense against tumors. By targeting the immunosuppressive tumor microenvironment, Macomics aims to leverage disease-specific macrophage biology, thereby enabling healthcare providers and pharmaceutical companies to offer significant clinical benefits to patients suffering from cancer. Through its innovative approach, Macomics is dedicated to advancing precision medicines in the fight against cancer.

NodThera is a UK-based biotechnology company focused on developing novel inhibitors of the NLRP3 inflammasome for treating inflammatory and neuroinflammatory diseases. Established in 2016, it operates laboratories in Little Chesterford (UK) and Seattle (US), with corporate offices in Lexington (US). The company's primary research involves inflammasomes, multi-protein complexes targeting conditions such as arthritis, atherosclerosis, Alzheimer's disease, diabetes, and certain cancers.

LUNAC Therapeutics is a biotechnology company focused on the development of advanced oral anticoagulant drugs aimed at treating and preventing life-threatening thrombotic events. The company's innovative drug formulations are designed to minimize bleeding risks in patients, allowing healthcare providers to manage high-risk patients with safe dose escalation. By addressing critical needs in anticoagulation therapy, LUNAC Therapeutics seeks to improve patient outcomes and enhance treatment options in the healthcare landscape.

Epsilogen Ltd is an immuno-oncology company based in London, United Kingdom, founded in 2016. The company specializes in developing immunoglobulin E (IgE) antibodies aimed at treating cancer. Epsilogen offers a portfolio of IgE candidates that specifically target cancer antigens such as HER2, EGFR, and PD-L1. Its innovative IgE platform supports the development and validation of novel antibodies, allowing for enhanced potency, improved tumor access, and a prolonged presence in tissue. This focus on IgE-based therapies positions Epsilogen to provide effective treatment options for patients with solid tumors.

NodThera is a UK-based biotechnology company focused on developing novel inhibitors of the NLRP3 inflammasome for treating inflammatory and neuroinflammatory diseases. Established in 2016, it operates laboratories in Little Chesterford (UK) and Seattle (US), with corporate offices in Lexington (US). The company's primary research involves inflammasomes, multi-protein complexes targeting conditions such as arthritis, atherosclerosis, Alzheimer's disease, diabetes, and certain cancers.

AdoRx Therapeutics is a United Kingdom-based drug discovery company focused on developing cancer therapeutics by modulating the adenosine pathway. Founded in 2017 and headquartered in Edinburgh, it designs fit-for-purpose adenosine receptor antagonists to counteract high adenosine levels in the tumor microenvironment that suppress immune responses and hinder therapy. The company’s approach aims to overcome immune suppression and improve treatment outcomes, drawing on leadership with extensive experience in biotech and pharma and a track record of identifying multiple clinical candidates.

Enterprise Therapeutics is a United Kingdom-based drug discovery company founded in 2014 and based in Brighton. It develops novel disease-modifying therapies for respiratory diseases, including cystic fibrosis, asthma, and COPD, with a focus on addressing the underlying mechanisms of mucus congestion to improve breathing, reduce lung infections, and enhance patient quality of life.

Mironid Limited is a biotechnology company based in Newhouse, United Kingdom, that specializes in drug discovery and development. Founded in 2014, Mironid focuses on creating innovative drug candidate molecules that modulate key cell signaling proteins to address degenerative kidney diseases, chronic inflammatory diseases, and cancer. The company's pipeline includes unique compounds designed to treat these conditions, utilizing a Physiology Mirroring Approach that aligns drug target environments with those found in living cells. Mironid aims to identify and validate novel drug targets, particularly in areas with significant unmet medical needs, by leveraging advanced technologies to streamline and enhance the drug discovery process. Through its dedicated efforts, Mironid seeks to develop differentiated therapies that improve patient health and quality of life.

Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutic compounds through inhibiting the complement system for treating autoimmune and inflammatory diseases. Its lead product candidate, pegcetacoplan, is in Phase III trials for geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, among other indications.

Epsilogen Ltd is an immuno-oncology company based in London, United Kingdom, founded in 2016. The company specializes in developing immunoglobulin E (IgE) antibodies aimed at treating cancer. Epsilogen offers a portfolio of IgE candidates that specifically target cancer antigens such as HER2, EGFR, and PD-L1. Its innovative IgE platform supports the development and validation of novel antibodies, allowing for enhanced potency, improved tumor access, and a prolonged presence in tissue. This focus on IgE-based therapies positions Epsilogen to provide effective treatment options for patients with solid tumors.

Eternygen is a Berlin-based biotechnology company founded in 2012 that specializes in the research and development of small molecule therapies for dietary-related metabolic diseases. The company focuses on inhibitors of the sodium-coupled citrate transporter NaCT, a key regulator of lipid metabolism implicated in fatty liver, diabetes, and obesity. By leveraging a network of scientists and contract research organizations, Eternygen advances novel drug candidates aimed at safe and effective restoration of metabolic balance in patients affected by these widespread conditions.

Enterprise Therapeutics is a United Kingdom-based drug discovery company founded in 2014 and based in Brighton. It develops novel disease-modifying therapies for respiratory diseases, including cystic fibrosis, asthma, and COPD, with a focus on addressing the underlying mechanisms of mucus congestion to improve breathing, reduce lung infections, and enhance patient quality of life.

Mironid Limited is a biotechnology company based in Newhouse, United Kingdom, that specializes in drug discovery and development. Founded in 2014, Mironid focuses on creating innovative drug candidate molecules that modulate key cell signaling proteins to address degenerative kidney diseases, chronic inflammatory diseases, and cancer. The company's pipeline includes unique compounds designed to treat these conditions, utilizing a Physiology Mirroring Approach that aligns drug target environments with those found in living cells. Mironid aims to identify and validate novel drug targets, particularly in areas with significant unmet medical needs, by leveraging advanced technologies to streamline and enhance the drug discovery process. Through its dedicated efforts, Mironid seeks to develop differentiated therapies that improve patient health and quality of life.

Topas Therapeutics GmbH, established in 2013 and based in Hamburg, Germany, is a biotechnology company specializing in the development of nanoparticle-based therapeutics. The company's core focus is to induce antigen-specific immune tolerance, utilizing the liver's natural immunology capabilities to treat autoimmune diseases, allergies, and anti-drug antibodies. Topas' proprietary platform, Topas Particle Conjugates, targets liver sinusoidal endothelial cells, enabling tolerance against blood-borne antigens. The company has several clinical-stage programs, including TPM203 for pemphigus vulgaris, and collaborations with pharmaceutical giants like Eli Lilly and Boehringer Ingelheim. Topas Therapeutics is backed by prominent investors such as Epidarex Capital, Gimv, EMBL Ventures, Evotec, and Boehringer Ingelheim Venture Fund.

Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutic compounds through inhibiting the complement system for treating autoimmune and inflammatory diseases. Its lead product candidate, pegcetacoplan, is in Phase III trials for geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, among other indications.

Caldan Therapeutics is a spinout from the University of Glasgow and the University of Southern Denmark focused on developing therapeutics that modulate free fatty acid receptors to address metabolic diseases, including Type 2 Diabetes, with potential applications in non-alcoholic steatohepatitis and inflammatory conditions. Building on a long-term collaboration between leading researchers, the company seeks to target multiple aspects of diabetes pathology, such as insulin secretion, insulin sensitivity, and islet cell protection, while aiming to reduce inflammatory activity in muscle, liver, and adipose tissue. The approach centers on delivering glucose-lowering effects by modulating receptor pathways implicated in diabetes and related inflammatory diseases.

Confluence Life Sciences, Inc. is a drug discovery company based in Saint Louis, Missouri, specializing in the design and development of mechanistically novel kinase inhibitors for human and animal health care. Founded in 2010, the company utilizes its KINect technology platform to identify and develop new drugs targeting key enzymes involved in cancer growth, survival, and metastasis, as well as in chronic inflammatory diseases. Confluence Life Sciences distinguishes itself by focusing on novel binding sites and previously undrugged kinases, addressing challenges that other programs have overlooked. The company is supported by a team of experts with extensive pharmaceutical experience in kinase inhibitor discovery and development, enabling it to pursue innovative strategies and targets. Confluence Life Sciences aims to establish scientific and business collaborations to enhance its program pipeline, which follows a cycle of discovery, development, and partnership to meet unmet medical needs.

Funderbeam is a platform connecting companies seeking investment with potential investors, facilitating equity stake transactions. Founded in 2013, it offers services including funding management, legal support, and investor networking.

Enterprise Therapeutics is a United Kingdom-based drug discovery company founded in 2014 and based in Brighton. It develops novel disease-modifying therapies for respiratory diseases, including cystic fibrosis, asthma, and COPD, with a focus on addressing the underlying mechanisms of mucus congestion to improve breathing, reduce lung infections, and enhance patient quality of life.

Clyde Biosciences is a developer of cardiac cell analysis solutions that provide human-relevant data to de-risk drug development. The company creates cell-based assays and analytics to reveal how drug compounds affect heart cells, enabling assessment of efficacy and potential cardiotoxicity in early research. Its offerings include cellOPTIQ, an optical action potential assay that measures drug effects on human cardiomyocytes, and XTENDSR, which quantifies drug-induced changes in cardiac sarcoplasmic reticulum function. By translating cellular responses into functional cardiomyocyte data, Clyde Biosciences supports pharmaceutical and biotechnology companies in identifying safety risks earlier and guiding molecule selection. Headquartered in Glasgow, United Kingdom, the company serves clients internationally and focuses on delivering human-relevant, mechanistic insights to improve the safety profile of new medicines.

Enterprise Therapeutics is a United Kingdom-based drug discovery company founded in 2014 and based in Brighton. It develops novel disease-modifying therapies for respiratory diseases, including cystic fibrosis, asthma, and COPD, with a focus on addressing the underlying mechanisms of mucus congestion to improve breathing, reduce lung infections, and enhance patient quality of life.

Sirakoss is a Scotland-based medical device company specializing in the development of synthetic bone graft substitutes. The company focuses on creating innovative solutions for trauma, spine, craniomaxillofacial, and dental applications. Sirakoss utilizes its proprietary MaxSi Graft technology, available in granular and putty forms, to effectively address spinal fusions and bone defects. This technology is designed to aid in the fusion of bones, helping to correct congenital or degenerative conditions, ultimately facilitating faster recovery for patients and promoting a healthier lifestyle.

Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutic compounds through inhibiting the complement system for treating autoimmune and inflammatory diseases. Its lead product candidate, pegcetacoplan, is in Phase III trials for geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, among other indications.

Confluence Life Sciences, Inc. is a drug discovery company based in Saint Louis, Missouri, specializing in the design and development of mechanistically novel kinase inhibitors for human and animal health care. Founded in 2010, the company utilizes its KINect technology platform to identify and develop new drugs targeting key enzymes involved in cancer growth, survival, and metastasis, as well as in chronic inflammatory diseases. Confluence Life Sciences distinguishes itself by focusing on novel binding sites and previously undrugged kinases, addressing challenges that other programs have overlooked. The company is supported by a team of experts with extensive pharmaceutical experience in kinase inhibitor discovery and development, enabling it to pursue innovative strategies and targets. Confluence Life Sciences aims to establish scientific and business collaborations to enhance its program pipeline, which follows a cycle of discovery, development, and partnership to meet unmet medical needs.

Edinburgh Molecular Imaging Limited is a biotechnology company based in Edinburgh, United Kingdom, specializing in the development of advanced imaging technologies for medical applications. Founded in 2014, the company initially focused on creating fluorescent optical imaging agents to assist in the detection and surgical guidance of cancer. Its flagship product, EMI-137, has successfully progressed through phase 2b clinical trials for colorectal cancer. In 2019, Edinburgh Molecular Imaging transitioned its focus to therapeutics, leveraging its expertise in molecular imaging to develop a systemic radiotheragnostic platform targeting c-Met. This platform includes the investigational agents [Ga68]EMP-10X and [Lu177/Ac225]EMP-10X, which have already shown proof of concept in clinical trials involving patients. The company's team possesses extensive experience in medicinal chemistry, biochemistry, and clinical development, positioning Edinburgh Molecular Imaging as a key player in the advancement of image-guided therapies for cancer diagnosis and treatment.

Leucid Bio is a biotechnology company focused on developing cell therapies for refractory solid tumors. It translates over two decades of King's College London research in CAR-T therapies, led by an experienced management team with scientific and commercial expertise.